Hemorrane - Glucocorticosteroid. Inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.
Inhibits the activity of phospholipase A2 which leads to suppression of the synthesis of prostaglandins and leukotrienes. Suppresses the release of COX (mainly COX-2), which also helps to reduce production of prostaglandins.
Reduces the number of circulating lymphocytes (T-and B-cells), monocytes, eosinophils and basophils as a result of their displacement from the vascular bed to lymphoid tissue, suppresses the formation of antibodies.
Hemorrane suppresses the release of pituitary ACTH and beta-lipotropin but does not reduce the level of circulating beta-endorphin. Inhibits the secretion of TSH and FSH.
With direct application of the receptacles has a vasoconstrictor effect.
Hemorrane has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats. Stimulates gluconeogenesis, promotes the capture of amino acids by the liver and kidneys and increases the activity of enzymes of gluconeogenesis. In the liver of Hemorrane increases glycogen deposition by stimulating the activity of glycogen synthase and synthesis of glucose from the products of protein metabolism. Increased blood glucose activates the secretion of insulin.
Hemorrane suppresses the seizure of glucose by fat cells that leads to activation of lipolysis. However, due to increased secretion of insulin is stimulation of lipogenesis which leads to the accumulation of fat.
This medication has catabolic effect in lymphoid and connective tissue, muscle, adipose tissue, skin, bone tissue; to a lesser extent than the mineralocorticoid affects the processes of water and electrolyte metabolism: promotes the excretion of potassium ions and calcium, delay in the body of sodium and water. Osteoporosis and Itsenko-Cushing\'s syndrome are the main factors limiting the long-term therapy of GCS. As a result of catabolic actions may suppress growth in children.
In high doses Hemorrane may increase the excitability of brain tissue and contributes to lowering the threshold of convulsive readiness. It stimulates the excessive production of hydrochloric acid and pepsin in the stomach that promotes the development of peptic ulcers.
For systems use therapeutic activity of Hemorrane caused by anti-inflammatory, anti-allergic, immunosuppressive and antiproliferative action. When external and local application the therapeutic activity of Hemorrane is due to anti-inflammatory, anti-allergic and antiexudative (due to vasoconstrictor effect) action. For anti-inflammatory activity this medicine is 4 times weaker than prednisolone, at mineralocorticoid activity is superior to other GCS.
Hemorrane is a glucocorticosteroid. Hemorrane inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.
(Systemic use):Endocrine disordes ( primary or secondary adrenocortical insufficiency ).shock unresponsive to conVentional therapy if adrenocortical insufficiency exists or is suspected, Rheumati c disorders ( post – traumatic osteoarthritis, synovitis of osteoarthritis, Rheumatoid arthritis, Acute and subacute bursitis. Epicondylitis, Acute nonspecific tenosynovitis, Acute gouty arthritis, Psoriatic arthritis Collagen diseases ( systemic lupus erythematosus, Acute rheumatic Carditis, systemic dermatomysitis ), Dermatologic disease ( Pemphigus, Severe erythma multiforme, Exfoliative dermatitis, Severe psoriasis ) ophthalmic diseases, ( in allergic and inflammatory processes involving the eye, such as : Herpes Zoster ophthalmicus, Iritis, iridocy clitis, chorioretinitis, Keratitis ), Gastrointestinal diseases ( ulcerative colitis systemic theropy ) Respiratory diseases ( symptomatic sarcoidosis, Berylliosis ) Hematologic disorders ( Acquired [ autoimmune ] hemolytic anemia ) Neoplastic disease. (Topical use):variety of skin conditions (e.g., insect bites, poison oak/ivy, eczema, dermatitis, allergies, rash, itching of the outer female genitals, anal itching). Hemorrane reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a mild corticosteroid.